Relaxing restrictions at the pace of vaccination increases freedom and guards against further COVID-19 waves

@article{Bauer2021RelaxingRA,
  title={Relaxing restrictions at the pace of vaccination increases freedom and guards against further COVID-19 waves},
  author={Simon Bauer and Sebasti{\'a}n Contreras and Jonas Dehning and Matthias Linden and Emil Iftekhar and Sebastian B. Mohr and {\'A}lvaro Olivera-Nappa and Viola Priesemann},
  journal={PLoS Computational Biology},
  year={2021},
  volume={17}
}
Mass vaccination offers a promising exit strategy for the COVID-19 pandemic. However, as vaccination progresses, demands to lift restrictions increase, despite most of the population remaining susceptible. Using our age-stratified SEIRD-ICU compartmental model and curated epidemiological and vaccination data, we quantified the rate (relative to vaccination progress) at which countries can lift non-pharmaceutical interventions without overwhelming their healthcare systems. We analyzed scenarios… 

A topic trend analysis on COVID-19 literature

The collected data can help build a more focused literature search between November 2019 and December 2021 when carrying out systematic and rapid reviews and the findings can give a complete picture on the topic.

Insights into Controlling the Spread of COVID-19: A Study Inspired by Seven of the Earliest Vaccinated Countries

This study delineated the spread of CO VID-19, human mobility patterns, widespread vaccination coverage, and government stringency measures on the overall control of COVID-19.

The heterogeneous mixing model of COVID-19 with interventions

Framing policies to mobilize citizens' behavior during a crisis: Examining the effects of positive and negative vaccination incentivizing policies

The COVID-19 pandemic has highlighted the issue of mobilization policies, that is, government practices directed at making the mass public voluntarily perform various behaviors for the collective

Who and which regions are at high risk of returning to poverty during the COVID-19 pandemic?

Pandemics such as COVID-19 and their induced lockdowns/travel restrictions have a significant impact on people’s lives, especially for lower-income groups who lack savings and rely heavily on

A Case for Cross-Border Governance? A Comparative Trend Assessment of COVID-19 Transmission, Vaccination, and Outcomes Among 35 Nations in Europe Across 18 months

Mass population vaccination appeared to be effective in reducing COVID-19 case severity and mortality rates, and vaccination equity and pan-European commitment for cross-border governance appear to be the way forward to ensure populations' return to "normality".

Polarimetric imaging for the detection of synthetic models of SARS-CoV-2: a proof of concept (preprint)

Objective: To conduct a proof-of-concept study of the detection of two synthetic models of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using polarimetric imaging. Methods: Two

Survey of awareness, attitudes, and compliance with COVID-19 measures among Vermont residents

Examining residents’ awareness, attitudes, and compliance with COVID-19 public health guidelines in Vermont shows that resistance to public health guidance is a partisan challenge even in states with high compliance, and identifies populations that are less supportive or hesitant to follow guidelines.

Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes

The VAP-SIRS model is proposed that considers possibly lower restrictions for the VP holders than for the rest of the population, imperfect vaccination effectiveness against infection, rates of (re-)vaccination and waning immunity, fraction of never-vaccinated, and the increased transmissibility of the Delta variant.

References

SHOWING 1-10 OF 91 REFERENCES

Controlling the pandemic during the SARS-CoV-2 vaccination rollout

It is predicted that relaxing measures completely or to the extent as in autumn 2020 could launch a wave starting in April 2021, and that substantial control efforts prove necessary throughout 2021.

Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine.

Analysis of a real-world dataset of positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test results after inoculation with the BNT162b2 messenger RNA vaccine found that the viral load was substantially reduced for infections occurring 12-37 d after the first dose of vaccine.

The variant gambit: COVID-19’s next move

Estimating the burden of SARS-CoV-2 in France

France has been heavily affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and went into lockdown on 17 March 2020, and population immunity appears to be insufficient to avoid a second wave if all control measures are released at the end of the lockdown.

Inferring high-resolution human mixing patterns for disease modeling

A data-driven approach to generate effective population-level contact matrices by using highly detailed macro (census) and micro (survey) data on key socio-demographic features to model the spread of airborne infectious diseases.

COVID-19 Impfquoten-Monitoring in Deutschland (COVIMO) –1

  • Report. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Projekte_RKI/covimo_ studie_bericht_1.pdf,
  • 2021

The challenges of containing SARS-CoV-2 via test-trace-and-isolate

The results suggest that TTI alone is insufficient to contain an otherwise unhindered spread of SARS-CoV-2, implying that complementary measures like social distancing and improved hygiene remain necessary.

Decreased SARS-CoV-2 viral load following vaccination

Analysis of positive SARS-CoV-2 test results following inoculation with the BNT162b2 mRNA vaccine finds that the viral load is reduced 4-fold for infections occurring 12-28 days after the first dose of vaccine.

Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom

Overall, COVID-19 vaccination reduced the number of new SARS-CoV-2 infections, with the largest benefit received after two vaccinations and against symptomatic and high viral burden infections, and with no evidence of a difference between the BNT162b2 and ChAdOx1 vaccines.
...